Compare Royal Bank of Canada (RY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs State Street SPDR S&P Biotech ETF — how do they compare? Royal Bank of Canada trades at $212.56 (market cap $292.32B), while State Street SPDR S&P Biotech ETF trades at $159.15. The key difference: Royal Bank of Canada pays a 2.37% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| RY | XBI | |
|---|---|---|
Market Cap | $292.32B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $217.87 | $164.28 |
52-Week Low | $134.80 | $86.92 |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $210.79, down slightly by 0.14% today. The stock shows a bullish technical trend with strong earnings performance, beating EPS estimates in three consecutive quarters. Revenue grew to $66.53 billion in 2025, with a net income margin of 31.85%. Analyst sentiment is mixed with a Buy consensus of 43% but a majority Hold rating. Recent insider selling and a dividend announcement highlight corporate activity.
RY presents a stable investment with solid profitability and dividend yield, but faces risks from high valuation multiples and macroeconomic sensitivity. Upside is supported by earnings growth and institutional holdings, while insider sales and debt levels warrant caution. The stock remains a core holding for dividend-focused portfolios amid moderate growth expectations.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
